Focus Partners Wealth’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.8M Sell
163,036
-6,250
-4% -$426K 0.01% 636
2026
Q1
$10.9M Buy
169,286
+45,387
+37% +$3.2M 0.01% 694
2025
Q4
$8.34M Buy
123,899
+806
+0.7% +$54.2K 0.01% 762
2025
Q3
$9.01M Sell
123,093
-9,550
-7% -$634K 0.01% 583
2025
Q2
$6.9M Buy
132,643
+11,828
+10% +$673K 0.01% 581
2025
Q1
$7.71M Buy
120,815
+40,260
+50% +$2.34M 0.02% 522
2024
Q4
$3.85M Buy
80,555
+1,049
+1% +$53.8K 0.01% 684
2024
Q3
$4.55M Sell
79,506
-13,147
-14% -$754K 0.01% 582
2024
Q2
$4.85M Buy
92,653
+1,308
+1% +$57.4K 0.02% 502
2024
Q1
$3.72M Buy
91,345
+11,552
+14% +$433K 0.03% 374
2023
Q4
$2.95M Buy
+79,793
New +$3.01M 0.04% 304

Other funds holding HALO

Focus Partners Wealth's HALO Position: Q2 2026 in Review

Focus Partners Wealth reduced its Halozyme (HALO) stake by 3.7% in Q2 2026, selling an estimated $426K and leaving 163,036 shares worth $12.8M. The position accounts for 0.01% of the portfolio, ranked #636.

Focus Partners Wealth first reported a position in HALO in Q4 2023 and has held it in 11 quarters since. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Focus Partners Wealth held 163,036 shares of Halozyme worth $12.8M as of Q2 2026.
  • Focus Partners Wealth sold 6,250 Halozyme shares in Q2 2026, an estimated $426K.
  • Halozyme made up 0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #636 holding.
  • Focus Partners Wealth first reported a position in Halozyme in Q4 2023 and has held it in 11 quarters since.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.